Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia

Obstetrics and Gynecology Clinics of North America

Volumn 37, Issue 2, 2010, Pages 239-253

  Silasi, Michelle ^a   Cohen, Bruce ^a   Karumanchi, S Ananth ^a,b   Rana, Sarosh ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Angiogenic factors; Hypertension; Preeclampsia; Pregnancy

Indexed keywords

ANGIOGENIC FACTOR; ANGIOTENSIN; BIOLOGICAL MARKER; CREATININE; ENDOGLIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HEME OXYGENASE; LACTATE DEHYDROGENASE; MAGNESIUM SULFATE; PLACENTAL GROWTH FACTOR; STEROID; URIC ACID; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANGIOGENIC PROTEIN; PROTEIN TYROSINE KINASE;

ACUTE KIDNEY FAILURE; ANGIOGENESIS; ARTICLE; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CLINICAL FEATURE; CYTOTROPHOBLAST; DELIVERY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; ECLAMPSIA; EMERGENCY CARE; EPIGASTRIC PAIN; EXTRAVILLOUS TROPHOBLAST CELL; FACE EDEMA; HAND EDEMA; HEADACHE; HEALTH STATUS; HELLP SYNDROME; HEMOCONCENTRATION; HEMOLYSIS; HIGH RISK PREGNANCY; HUMAN; HYPERTENSION; INTRAUTERINE GROWTH RETARDATION; LIVER FAILURE; LUNG EDEMA; MICROALBUMINURIA; NONHUMAN; ONSET AGE; OXYGEN TENSION; PATHOGENESIS; PERINATAL DEATH; PLACENTA DISORDER; PREDICTIVE VALUE; PREECLAMPSIA; PREGNANCY COMPLICATION; PREMATURE LABOR; PREMATURITY; PRIORITY JOURNAL; PROTEINURIA; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SEIZURE; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SOLUTIO PLACENTAE; THROMBOCYTOPENIA; TISSUE PERFUSION; TROPHOBLAST; UTERINE PERFUSION; VASCULARIZATION; VISUAL FIELD DEFECT; WOMEN'S HEALTH; FEMALE; FETUS DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; PLACENTA; PREGNANCY; REPRODUCTION; REVIEW;

ANGIOGENIC PROTEINS; FEMALE; FETAL DISEASES; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PLACENTA; PLACENTA DISEASES; PLACENTATION; PRE-ECLAMPSIA; PREGNANCY; PROTEIN-TYROSINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78650830910     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2010.02.013     Document Type: Article

References (95)

1. Roberts JM, Taylor RN, Musci TJ, et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989;161(5):1200-4.
2. Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 2009;24:147-58.
3. Sibai B, Dekker G, Kupferminc M. Preeclampsia. Lancet 2005;365(9461): 785-99.
4. Alderman BW, Sperling RS, Daling JR. An epidemiological study of the immunogenetic aetiology of pre-eclampsia. Br Med J (Clin Res Ed) 1986;292(6517): 372-4.
5. Bhattacharya S, Campbell DM, Liston WA. Effect of body mass index on pregnancy outcomes in nulliparous women delivering singleton babies. BMC Public Health 2007;7:168.
6. Roman H, Robillard PY, Hulsey TC, et al. Obstetrical and neonatal outcomes in obese women. West Indian Med J 2007;56(5):421-6.
7. Carr DB, Epplein M, Johnson CO, et al. A sisters risk: family history as a predictor of preeclampsia. Am J Obstet Gynecol 2005;193:965-72.
8. Esplin MS, Fausett MB, Fraser A, et al. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med 2001;344(12):867-72.
9. Tuffnell DJ, Jankowicz D, Lindow SW, et al. Outcomes of severe preeclampsia/ eclampsia in Yorkshire 1999/2003. BJOG 2005;112(7):875-80.
10. Skjaerven R, Wilcox AJ, Lie RT. The interval between pregnancies and the risk of preeclampsia. N Engl J Med 2002;346(1):33-8.
11. Cote AM, Brown MA, Lam E, et al. Diagnostic accuracy of urinary spot protein: creatinine ratio for proteinuria in hypertensive pregnant women: systematic review. BMJ 2008;336(7651):1003-6.
12. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003;102(1):181-92.
13. Buchbinder A, Sibai BM, Caritis S, et al. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol 2002;186(1):66-71.
14. Sibai BM. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol 2005;105(2):402-10.
15. Nisell H, Lintu H, Lunell NO, et al. Blood pressure and renal function seven years after pregnancy complicated by hypertension. Br J Obstet Gynaecol 1995; 102(11):876-81.
16. Ray JG, Vermeulen MJ, Schull MJ, et al. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005;366(9499):1797-803.
17. Irgens HU, Reisaeter L, Irgens LM, et al. Long-term mortality of mothers and fathers after preeclampsia: population-based cohort study. BMJ 2001; 323(7323):1213-7.
18. Sibai BM, Barton JR. Expectant management of severe preeclampsia remote from term: patient selection, treatment, and delivery indications. Am J Obstet Gynecol 2007;196(6):514, e1-9.
19. Bombrys AE, Barton JR, Nowacki EA, et al. Expectant management of severe preeclampsia at less than 27 weeks' gestation: maternal and perinatal outcomes according to gestational age by weeks at onset of expectant management. Am J Obstet Gynecol 2008;199(3):247, e1-6.
20. Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild preeclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 2009;374(9694):979-88.
21. Norwitz ER, Repke JT. Preeclampsia prevention and management. J Soc Gynecol Investig 2000;7(1):21-36.
22. Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000;183(1):S1-22.
23. Newman RB, Eddy GL. Association of eclampsia and hydatidiform mole: case report and review of the literature. Obstet Gynecol Surv 1988;43(4):185-90.
24. Brittain PC, Bayliss P. Partial hydatidiform molar pregnancy presenting with severe preeclampsia prior to twenty weeks gestation: a case report and review of the literature. Mil Med 1995;160(1):42-4.
25. Shembrey MA, Noble AD. An instructive case of abdominal pregnancy. Aust N Z J Obstet Gynaecol 1995;35(2):220-1.
26. Matsuo K, Kooshesh S, Dinc M, et al. Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature. Am J Perinatol 2007;24(4):257-66.
27. Seval Y, Korgun ET, Demir R. Hofbauer cells in early human placenta: possible implications in vasculogenesis and angiogenesis. Placenta 2007;28(8-9):841-5.
28. Khan S, Katabuchi H, Araki M, et al. Human villous macrophage-conditioned media enhance human trophoblast growth and differentiation in vitro. Biol Reprod 2000;62(4):1075-83.
29. Zhou Y, Fisher SJ, Janatpour M, et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? J Clin Invest 1997;99(9):2139-51.
30. Jauniaux E, Watson AL, Hempstock J, et al. Onset of maternal arterial blood flow and placental oxidative stress. A possible factor in human early pregnancy failure. Am J Pathol 2000;157(6):2111-22.
31. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu 1972;1:177-91.
32. Gerretsen G, Huisjes HJ, Elema JD. Morphological changes of the spiral arteries in the placental bed in relation to pre-eclampsia and fetal growth retardation. Br J Obstet Gynaecol 1981;88(9):876-81.
33. Meekins JW, Pijnenborg R, Hanssens M, et al. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994;101(8):669-74.
34. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 1997;99(9):2152-64.
35. Kopcow HD, Karumanchi SA. Angiogenic factors and natural killer (NK) cells in the pathogenesis of preeclampsia. J Reprod Immunol 2007;76:23-9.
36. Connolly DT. Vascular permeability factor: a unique regulator of blood vessel function. J Cell Biochem 1991;47(3):219-23.
37. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A(164/165) and PlGF: roles in angiogenesis and arteriogenesis. Trends Cardiovasc Med 2003;13(5):169-75.
38. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006; 312(5):549-60.
39. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005;109(3):227-41.
40. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20(21):4368-80.
41. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380(6573):435-9.
42. Ferrara N, Carver-MooreK, ChenH, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380(6573):439-42.
43. Zhang F, Tang Z, Hou X, et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci U S A 2009;106(15):6152-7.
44. Yamazaki Y, Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol Divers 2006;10(4):515-27.
45. Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A 1998;95(20):11709-14.
46. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7(5):575-83.
47. Hiratsuka S, Nakamura K, Iwai S, et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002;2(4):289-300.
48. Murakami M, Zheng Y, Hirashima M, et al. VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment. Arterioscler Thromb Vasc Biol 2008;28(4):658-64.
49. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996;226(2):324-8.
50. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001;26(1):25-35.
51. Jones RL, Stoikos C, Findlay JK, et al. TGF-beta superfamily expression and actions in the endometrium and placenta. Reproduction 2006;132(2):217-32.
52. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350(7):672-83.
53. Wathen KA, Tuutti E, Stenman UH, et al. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab 2006;91(1):180-4.
54. McKeeman GC, Ardill JE, Caldwell CM, et al. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004;191(4):1240-6.
55. Hertig A, Berkane N, Lefevre G, et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 2004;50(9): 1702-3.
56. Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004;190(6): 1541-7 [discussion: 1547-50].
57. Powers RW, Roberts JM, Cooper KM, et al. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia. Am J Obstet Gynecol 2005;193(1):185-91.
58. Livingston JC, Chin R, Haddad B, et al. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol 2000;183(6):1554-7.
59. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355(10):992-1005.
60. Bdolah Y, Lam C, Rajakumar A, et al. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia? Am J Obstet Gynecol 2008;198(4):428 e421-6.
61. Kanter D, Lindheimer MD, Wang E, et al. Angiogenic dysfunction in molar pregnancy. Am J Obstet Gynecol 2010;202(2):184, e1-5.
62. Koga K, Osuga Y, Tajima T, et al. Elevated serum soluble fms-like tyrosine kinase 1 (sFlt1) level in women with hydatidiform mole. Fertil Steril 2009. [Epub ahead of print].
63. Bdolah Y, Palomaki GE, Yaron Y, et al. Circulating angiogenic proteins in trisomy. Am J Obstet Gynecol 2006;194(1):239-45.
64. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111(5):649-58.
65. Nagamatsu T, Fujii T, Kusumi M, et al. Cytotrophoblasts up-regulate soluble fmslike tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004;145(11):4838-45.
66. Shore VH, Wang TH, Wang CL, et al. Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta 1997; 18(8):657-65.
67. Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008;93(1):260-6.
68. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004;95(9):884-91.
69. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12(6):642-9.
70. Bergmann A, Ahmad S, Cudmore M, et al. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med 2009. [Epub ahead of print].
71. Li Z, Zhang Y, Ying Ma J, et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007;50(4):686-92.
72. Heydarian M, McCaffrey T, Florea L, et al. Novel splice variants of sFlt1 are up-regulated in preeclampsia. Placenta 2009;30(3):250-5.
73. Thomas CP, Andrews JI, Raikwar NS, et al. A recently evolved novel trophoblastenriched secreted form of fms-like tyrosine kinase-1 variant is up-regulated in hypoxia and preeclampsia. J Clin Endocrinol Metab 2009;94(7):2524-30.
74. Sela S, Itin A, Natanson-Yaron S, et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 2008;102(12):1566-74.
75. Zhou CC, Ahmad S, Mi T, et al. Angiotensin II induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res 2007;100(1):88-95.
76. Cudmore M, Ahmad S, Al-Ani B, et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007;115(13): 1789-97.
77. Irani RA, Xia Y. The functional role of the renin-angiotensin system in pregnancy and preeclampsia. Placenta 2008;29(9):763-71.
78. Park CW, Park JS, Shim SS, et al. An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of midtrimester genetic amniocentesis is a risk factor for preeclampsia. Am J Obstet Gynecol 2005;193: 984-9.
79. Levine RJ, Thadhani R, Qian C, et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005;293(1):77-85.
80. Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and antiangiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009;22(11): 1021-38.
81. Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010;202(2):161, e1-11.
82. Sunderji S, Gaziano E, Wothe D, et al. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 2010;202(1):40, e1-7.
83. Signore C, Mills JL, Qian C, et al. Circulating angiogenic factors and placental abruption. Obstet Gynecol 2006;108(2):338-44.
84. Signore C, Mills JL, Qian C, et al. Circulating soluble endoglin and placental abruption. Prenat Diagn 2008;28(9):852-8.
85. Poon LC, Karagiannis G, Leal A, et al. Hypertensive disorders in pregnancy: screening by uterine artery Doppler imaging and blood pressure at 11-13 weeks. Ultrasound Obstet Gynecol 2009;34(5):497-502.
86. Poon LC, Staboulidou I, Maiz N, et al. Hypertensive disorders in pregnancy: screening by uterine artery Doppler at 11-13 weeks. Ultrasound Obstet Gynecol 2009;34(2):142-8.
87. Grill S, Rusterholz C, Zanetti-Dallenbach R, et al. Potential markers of preeclampsia-a review. Reprod Biol Endocrinol 2009;7:70.
88. Stepan H, Unversucht A, Wessel N, et al. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007;49(4):818-24.
89. Stepan H, Geipel A, Schwarz F, et al. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 2008;198(2):175, e171-6.
90. Savvidou MD, Noori M, Anderson JM, et al. Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation. Ultrasound Obstet Gynecol 2008;32(7): 871-6.
91. Espinoza J, Romero R, Nien JK, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007;196(4):326, e1-13.
92. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004;104(6): 1367-91.
93. Gilbert JS, Verzwyvelt J, Colson D, et al. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension 2010;55(2): 380-5.
94. Vikse BE, Irgens LM, Leivestad T, et al. Preeclampsia and the risk of end-stage renal disease. N Engl J Med 2008;359(8):800-9.
95. Levine RJ, Vatten LJ, Horowitz GL, et al. Preeclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study. BMJ 2009;339:b4336.